Who can use pemazyre(pemigatinib)?

Cholangiocarcinoma

Pemigatinib is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma that is unresectable, has received prior treatment, and harbors fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements detected by an FDA-approved test.

Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Pemigatinib is indicated for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLN) harboring fibroblast growth factor receptor 1 (FGFR1) rearrangements.

Related Columns

pemazyre(pemigatinib)

1. Cholangiocarcinoma 2. Myeloid/lymphoid neoplasms with FGFR1 rearrangement

WeChat Scan
Free Inquiry

What are the Indications for Pemigatinib (Pemazyre)?

Pemigatinib (Pemazyre) is an innovative kinase inhibitor. By specifically targeting the fibroblast growth factor receptor (FGFR) pathway, it provides a precision treatment option for patients with mal...

What is Pemazyre (Pemigatinib)?

Pemazyre (pemigatinib) is a targeted therapy drug approved for marketing by the U.S. FDA in 2020. It belongs to the class of kinase inhibitors and is mainly used for the treatment of specific types of...

What is Pemazyre (Pemigatinib)?

Pemazyre (pemigatinib) is a targeted therapeutic drug approved for marketing by the U.S. FDA in 2020. It belongs to the class of kinase inhibitors and is mainly used for the treatment of specific type...

Targeted Mechanism of Action of Pemigatinib

Pemigatinib is a novel targeted drug used for the treatment of cholangiocarcinoma and myeloid/lymphoid neoplasms. By inhibiting the activation of the FGFR1 receptor and interfering with the abnormal s...